4//SEC Filing
Dorling Janet 4
Accession 0001062993-23-020834
CIK 0001042074other
Filed
Nov 13, 7:00 PM ET
Accepted
Nov 14, 5:56 PM ET
Size
8.8 KB
Accession
0001062993-23-020834
Insider Transaction Report
Form 4
Dorling Janet
Chief Commercial Officer
Transactions
- Exercise/Conversion
Common Stock
2023-11-10$4.63/sh+7,000$32,410→ 7,000 total - Sale
Common Stock
2023-11-10$15.24/sh−7,000$106,700→ 0 total - Exercise/Conversion
Employee Stock Option (right to buy)
2023-11-10−7,000→ 73,000 totalExercise: $4.63Exp: 2031-04-04→ Common Stock (7,000 underlying)
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on August 9, 2023.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.15 to $15.46, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The option grant vests as to 1/36 of the underlying shares monthly from April 5, 2021.
Issuer
CymaBay Therapeutics, Inc.
CIK 0001042074
Entity typeother
Related Parties
1- filerCIK 0001738144
Filing Metadata
- Form type
- 4
- Filed
- Nov 13, 7:00 PM ET
- Accepted
- Nov 14, 5:56 PM ET
- Size
- 8.8 KB